DLBS3233
Phase 3Small molecule
DLBS3233 is one of 100 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DLBS3233
DDexa Medica Group
Phase 3
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome1 trial
Diabetes Mellitus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DLBS3233. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDexa Medica Group